Hoth Therapeutics, Inc. (NASDAQ: HOTH) is delighted to announce that the initial patient has been dosed in Phase 2a of their HT-001 therapy for skin toxicities caused by EGFRi. This represents a dynamic milestone in the company’s mission to provide compassionate and efficacious solutions to improving patients’ quality of life. With the commencement of this study, Hoth Therapeutics seeks to bring life-changing progress to individuals impacted by these skin complications.
Robb Knie, Chief Executive Officer of Hoth Therapeutics, is passionate about discovering new treatments for cancer patients undergoing EGFR inhibitor therapy. Excited about the potential of their clinical journey, Knie said, “We are delighted to have the opportunity to help those in need who suffer from side effects due to this therapy.” He expressed his hope that their efforts would “contribute to the advancement of treatment options” for these individuals.
This exciting clinical trial is exploring the potential of the topical treatment, HT-001, for reducing the skin toxicities caused by EGFR inhibition therapies. It’s a randomized, placebo-controlled study in Phase 2a that measures the efficacy, safety, and tolerability of HT-001. Be part of this groundbreaking research and prove the potential of HT-001!
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a pioneering biopharmaceutical company striving to revolutionize patient care by developing cutting-edge treatments to benefit the lives of those who need it most. Our mission is to take innovative drugs from concept to clinical trial in a short timeframe, allowing us to make a real difference in the lives of patients and their loved ones.
We strive to do this through patient-centric collaborations with scientists, clinicians, and key opinion leaders, in order to bring the latest advances in medical research to the public. Together, we can make a meaningful difference in the lives of those who need it most.